Drugs / Bradykinin
Bradykinin
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04374500 | Jan → Oct 2006 | obesity disorder | Stefan Soderberg | Completed | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT02833207 | Apr 2012 → Nov 2021 | obesity disorder | University of Wisconsin, Madison | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00868855 | Dec 2003 → Dec 2010 | coronary artery disorder | Vanderbilt University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00004575 | Feb 2000 → Oct 2001 | — | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 1 | NCT00160888 | Nov 1999 → Dec 2006 | — | Heidelberg University | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00166166 | Jul 2002 → Jan 2013 | hyperlipidemia | Emory University | Terminated | No outcome recorded |
| Phase not applicable4 trials · 1 met primary | ||||||
| — | NCT00780637 | Oct 2008 → Jan 2011 | — | Vanderbilt University | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT00780377 | Oct 2008 → Jan 2011 | — | Vanderbilt University | Withdrawn | No outcome recorded |
| — | NCT00685945 | Dec 2007 → Jan 2009 | obesity disorder | Vanderbilt University | Completed | Met primary |
| — | NCT00780481 | Jan 2007 → Jan 2011 | obesity disorder | Vanderbilt University | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT03738878 Comparator | Nov 2018 → Dec 2024 | hypertensive disorder | Vanderbilt University Medical Center | Terminated | No outcome recorded |
| — | NCT01413542 Comparator | Nov 2011 → Jul 2013 | hypertensive disorder, type 2 diabetes mellitus | Vanderbilt University | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bradykinin | “Agonists include: ATP, Bradykinin (BK), Isoproterenol (ISO), and Acetylcholine (Ach), will be infused 3 times each (order randomized).” NCT02833207 ↗11“bradykinin (endothelium-dependent vasodilator that releases tPA) at 100, 300 and 1,000 pmol/min” NCT04374500 ↗ |
| Known as | BRS-640 | ChEMBL registry synonym — accepted as the source's own label CHEMBL406291 ↗ |
| Known as | Callidin i | ChEMBL registry synonym — accepted as the source's own label CHEMBL406291 ↗ |
| Known as | Kallidin i | ChEMBL registry synonym — accepted as the source's own label CHEMBL406291 ↗ |
| Known as | Kallidin-9 | ChEMBL registry synonym — accepted as the source's own label CHEMBL406291 ↗ |
| Action | Activate | “Bradykinin stimulates the release of EDHF” NCT00004575 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL406291 ↗ |
| Route | Other | “Small doses of four drugs-bradykinin, sodium nitroprusside, miconazole, and LNMMA-will be given through the arterial catheter” NCT00004575 ↗ |